Assessment of Efficacy of Vardenafil in Subjects With Erectile Dysfunction and Diabetes, Hypertension or Hyperlipidemia

Official Title: “A Randomized, Open-Label, Multi-Center, Parallel Group Study to Investigate the Efficacy and Safety of Vardenafil in Comparison to Tadalafil in Males With Erectile Dysfunction and a Diagnosis of Diabetes, Hypertension or Hyperlipidemia”

Assessment of efficacy of vardenafil in subjects with erectile dysfunction and diabetes, hypertension or hyperlipidemia

Intervention(s) in this Clinical Trial

• Drug: Levitra (Vardenafil, BAY38-9456)
  • 10 mg one hour prior to sexual intercourse
• Drug: Tadalafil
  • 10 mg taken approximately 24 hours prior to sexual intercourse

Arms, Groups and Cohorts in this Clinical Trial

• Experimental: Arm 1
• Active Comparator: Arm 2

Primary Measures

• Sexual encounter profile question 3 observed within 15 minutes to 4 hours for vardenafil and 22 to 26 hours for the tadalafil group
  • Time Frame: 4 weeks
    Safety Issue?: No

Secondary Measures

• Sexual encounter profile question 2
  • Time Frame: 4 weeks
    Safety Issue?: No
• Hardness of erection
  • Time Frame: 4 weeks
    Safety Issue?: No
• Other diary based variables
  • Time Frame: 4 weeks
    Safety Issue?: No
• Safety and tolerability
  • Time Frame: 4 weeks
    Safety Issue?: Yes

Inclusion Criteria:

• Age: 18 years and older
• Males with erectile dysfunction
• Stable heterosexual relationship
• Medical history / diagnosis of diabetes mellitus and/or hypertension and/or hyperlipidemia

Exclusion Criteria:

• Primary hypoactive sexual desire
• History of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months
• Nitrate use
• Other exclusion criteria apply according to Summary of Product Characteristics

Gender Eligibility for this Clinical Trial: Male

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: Bayer Industry

Overall Clinical Trial Officials and Contacts

Bayer Study Director Study Director Bayer  

Information obtained from ClinicalTrials.gov on February 09, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00668109

Study ID Number: 10893

ClinicalTrials.gov Identifier: NCT00668109

Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Click here and search for drug information provided by the FDA

Click here and search for information on any recalls, market or product safety alerts by the FDA